Pharmaron Beijing (300759) Stock Price, Fundamentals & Analysis

What 300759 does

Pharmaron Beijing (300759) is a stock listed on the Shenzhen Stock Exchange in the Healthcare sector, specifically in the Biotechnology industry. Headquartered in Beijing, China, the company operates as a pharmaceutical research and development service platform across North America, Europe, Mainland China, Asia, and internationally. It works through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. Its services range from small molecule chemical drugs and antibodies to cell and gene therapy products, as well as API process development and analytical development.

Key numbers explained

• 43.5 CNY is the current price, representing the cost of one share in the local currency.
• The trailing P/E ratio of 47.3 compares the price to the last 12 months of earnings; a higher number can suggest the market expects strong future growth.
• The forward P/E ratio of 30.5 uses expected future earnings, offering a look at how the market prices what is coming next.
• Earnings per share, trailing 12 months of 0.92 CNY shows the portion of profit allocated to each share over the last year.
• The dividend yield of 0.46% indicates the annual dividend relative to the price; a low yield is common for growth-oriented biotech firms.
• Beta of 0.64 suggests the stock tends to be less volatile than the overall market.
• Market cap of 79.92 mld. CNY reflects the total market value of all outstanding shares.
• Revenue growth, year over year of 20.2% shows how quickly the top line has expanded recently.

What to watch

Pharma R&D services stocks like Pharmaron Beijing (300759) are often influenced by pipeline progress, regulatory decisions, and funding trends in the biotech ecosystem. Investors may track how the company's five business segments evolve, especially as it expands into areas such as cell and gene therapy. Being part of the Shenzhen Stock Exchange, the stock can be affected by broader Chinese market sentiment and sector rotation. For context, peers such as Yunnan Baiyao Group (000538) and Hualan Biological Engineering (002007) operate in related healthcare spaces, while Mindray (300760) and Aier Eye Hospital (300015) represent other Shenzhen-listed healthcare names. General factors to monitor include R&D spending, partnership announcements, and macroeconomic conditions that affect healthcare investment.